Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03480776 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ASA in Prevention of Ovarian Cancer (STICs and STONEs)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 30, 2026 → Dec 31, 2026
See other at-risk trials from Canadian Cancer Trials Group

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 30, 2026 to Dec 31, 2026 Show 5 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Study completion pushed from Sep 15, 2026 to Jun 30, 2027
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 1 of 2 entries
    • Site details revised at 4 of 17 sites
  2. Primary completion date: Dec 15, 2025 to Jun 30, 2026v36
  3. Primary completion date: Jun 30, 2025 to Dec 15, 2025
    • Study completion date: Dec 31, 2025 to Sep 15, 2026
    v35
  4. Primary completion date: Dec 15, 2024 to Jun 30, 2025
    • Study completion date: Sep 15, 2025 to Dec 31, 2025
    v34
  5. Primary completion date: Mar 31, 2024 to Dec 15, 2024
    • Study completion date: Dec 31, 2024 to Sep 15, 2025
    v33
Show 31 earlier versionsHide 31 earlier versions
  1. Re-verified, no change to tracked fieldsv32
  2. Start date: Apr 6, 2018 to Jul 24, 2018v31
  3. Primary completion date: Mar 31, 2023 to Mar 31, 2024v30 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 414 to confirmed 117
    • Study completion date: Dec 31, 2023 to Dec 31, 2024
    • Site details revised at 17 of 17 sites
  4. Study sites: 18 to 17v29
  5. Re-verified, no change to tracked fieldsv28
  6. Site contacts updated at 1 of 18 sitesv27
  7. Site details revised at 1 of 18 sitesv26
  8. Re-verified, no change to tracked fieldsv25
  9. Site contacts updated at 1 of 18 sitesv24
  10. Study sites: 16 to 18v23
  11. Study sites: 15 to 16v22
  12. Site details revised at 1 of 15 sitesv21
  13. Primary completion date: Mar 2023 to Mar 31, 2023
    • Study completion date: Dec 2023 to Dec 31, 2023
    v20
  14. Study sites: 14 to 15v19
  15. Study sites: 13 to 14v18
  16. Site details revised at 1 of 13 sitesv17
  17. Study sites: 11 to 13v16
  18. Study sites revised (11)v15
  19. Study sites revised (11)v14
  20. Study sites: 10 to 11v13
  21. Study sites: 9 to 10v12
  22. Eligibility criteria expanded, about 13 wordsv11
  23. Site details revised at 1 of 9 sitesv10
  24. Study sites: 8 to 9v9
  25. Study sites: 7 to 8v8
  26. Study sites: 6 to 7v7
  27. Study sites: 4 to 6v6
  28. Study sites: 2 to 4v5
  29. Re-verified, no change to tracked fieldsv4
  30. Study sites: 1 to 2v3
  31. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2018 to Apr 6, 2018
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action. Inflammation in the ovaries during ovulation is thought to contribute to the development of ovarian cancer, and, because ASA is an anti-inflammatory medication, it may help to prevent it.
Trial Details
NCT Number NCT03480776
Lead Sponsor Canadian Cancer Trials Group
Collaborators: Apotex Inc.
Conditions
(from sponsor)		 Ovarian Cancer Prevention
Enrollment 117 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov